Proteomics International, inVentiv Health Collaborate on Biosimilars Development | GenomeWeb

NEW YORK (GenomeWeb News) – Proteomics International recently announced an agreement with inVentiv Health Clinical aimed at the development of biosimilars.

As part of the deal, Perth, Australia-based Proteomics International's services aimed at structural characterization and quality control testing of proposed and referenced products will be combined with inVentiv's bioanalytical capabilities.

The New Jersey-based firm provides drug development services.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.